Related Experiment Video
Updated: Aug 12, 2026

Characterization of Human Monocyte-derived Dendritic Cells by Imaging Flow Cytometry: A Comparison between Two Monocyte Isolation Protocols
Published on: October 18, 2016
Anti-CD47 monoclonal antibody (B6H12) impairs the maturation and function of human dendritic cells
1Department of Hematology, Center of Bone Marrow Transplantation, The First Affiliated Hospital, Medical College of Zhejiang University, Hangzhou 310003, China.
Abstract:
To investigate the influence and mechanisms of CD47 engagement by its soluble mAb B6H12 on the maturation and function of cultured dendritic cells (DCs), monocyte-derived DCs were propagated in granulocyte-macrophage colony stimulating factor (GM-CSF) combined with lipopolysaccharide (LPS) and interleukin (IL)-4, in the presence or absence of soluble anti-CD47 monoclonal antibodies (anti-CD47 mAbs, B6H12). The characteristic morphology of DCs was identified by using the transmission electron microscopy. Flow cytometry was used to detect the cell surface phenotypes. The concentration of IL-12 P70 in supernatant was measured by ELISA. The antigen-presenting functions of DCs were determined in one-way mixed leukocyte reaction by BrdU-ELISA. Electrophoretic mobility shift assay (EMSA) was applied to examine the activity of NF-kappaB. The results indicated that the anti-CD47 mAbs markedly suppressed the expression of CD80, CD86, CD83, CD1a and HLA-DR on the surface of DCs (P < 0.05). The data of the mixed leukocyte reaction and IL-12 P70 production were consistent with the results by flow cytometry (P < 0.01). Pre-exposure to B6H12 mAb during the development of DCs resulted in a dramatic depletion of the DNA binding activity of NF-kappaB toward nucleus protein. Moreover, such an inhibition effect seemed to be dose dependent. In conclusion, the soluble mAb B6H12 inhibits the expression of the costimulatory molecules and MHCII molecules on the DCs. The antigen-presenting function of DCs was also impaired by B6H12. And these modulations are closely related with the depletive DNA binding activity of NF-kappaB. It is suggested that the soluble B6H12 exerts a negative effect on the maturation and function of in vitro cultured DCs due to inhibition of NF-kappaB binding activity.
Insights
Soluble anti-CD47 monoclonal antibody (mAb) B6H12 inhibits dendritic cell (DC) maturation and function. This inhibition is linked to reduced NF-kappaB activity, suppressing costimulatory and MHCII molecule expression on DCs.
Area of Science:
- Immunology
- Cell Biology
- Molecular Biology
Background:
- Dendritic cells (DCs) are crucial antigen-presenting cells regulating immune responses.
- CD47 is a cell surface receptor involved in immune cell interactions.
- The role of soluble anti-CD47 monoclonal antibodies (mAbs) in DC function requires further elucidation.
Purpose of the Study:
- To investigate the impact of soluble anti-CD47 mAb B6H12 on the maturation and function of cultured dendritic cells (DCs).
- To elucidate the underlying mechanisms, particularly the involvement of NF-kappaB signaling.
Main Methods:
- Monocyte-derived DCs were cultured with GM-CSF, LPS, and IL-4, with or without anti-CD47 mAb B6H12.
- Techniques included transmission electron microscopy, flow cytometry, ELISA, mixed leukocyte reaction (MLR), and electrophoretic mobility shift assay (EMSA).
- Analysis focused on DC surface markers, IL-12 P70 production, antigen-presenting capacity, and NF-kappaB DNA binding activity.
Main Results:
- Anti-CD47 mAb B6H12 significantly suppressed the expression of key DC maturation markers (CD80, CD86, CD83, CD1a, HLA-DR).
- DC antigen-presenting function, as assessed by MLR and IL-12 P70 production, was impaired by B6H12 treatment.
- B6H12 treatment led to a dose-dependent decrease in NF-kappaB DNA binding activity in DCs.
Conclusions:
- Soluble anti-CD47 mAb B6H12 inhibits the maturation and antigen-presenting function of in vitro cultured DCs.
- These inhibitory effects are associated with the suppression of NF-kappaB activation.
- B6H12 negatively modulates DC function by inhibiting NF-kappaB binding activity, impacting costimulatory and MHCII molecule expression.

